Ocular Oncology and Pathology最新文献

{"title":"Expert Opinions on Uveal Melanoma: Insights from the 58th Ophthalmic Oncology Group Meeting.","authors":"Gustav Stålhammar, Vicktoria Vishnevskia-Dai, Robert M Verdijk, Alexandre Moulin","doi":"10.1159/000541016","DOIUrl":"10.1159/000541016","url":null,"abstract":"<p><strong>Introduction: </strong>Clear evidence for the best clinical management of uveal melanoma is lacking in some areas. Therefore, reports on expert opinions in the field can be valuable.</p><p><strong>Methods: </strong>A questionnaire comprising 10 questions was distributed to potential participants of the 58th Ophthalmic Oncology Group Meeting in Stockholm, Sweden, in June 2024.</p><p><strong>Results: </strong>Among 34 respondents, 13 (38%) had >20 years of postresidency experience in ophthalmic oncology. The maximum recommended tumor thickness for ruthenium-106 plaque brachytherapy was 5.7 mm (SD 1.1). Twenty-three respondents (68%) indicated that radiological surveillance for metastatic disease should be conducted irrespective of primary tumor characteristics. A majority (74%) would treat a lesion with a 6 mm diameter and 1.5 mm thickness without waiting for evidence of growth if sufficient risk factors were present. Most experts did not currently recommend sampling of circulating tumor DNA or circulating tumor cells. There were no significant differences in responses based on the experience of respondents (≤20 vs. >20 years) or their annual volume of new cases (≤50 vs. >50).</p><p><strong>Conclusion: </strong>This article reports the opinions of 34 experts in ophthalmic oncology on various contemporary topics in uveal melanoma. The responses illustrate both agreements and differences in opinions among experts.</p>","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":"10 4","pages":"197-205"},"PeriodicalIF":0.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11627587/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142807708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Structural Competency for Ocular Oncologists and Pathologists.","authors":"Curtis E Margo","doi":"10.1159/000541182","DOIUrl":"10.1159/000541182","url":null,"abstract":"","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":"10 4","pages":"252-254"},"PeriodicalIF":0.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11627582/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142807749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spotlighting Turnover Costs for Pediatric Ocular Oncology Exams under Anesthesia.","authors":"David S Portney, Hakan Demirci","doi":"10.1159/000541659","DOIUrl":"10.1159/000541659","url":null,"abstract":"<p><strong>Introduction: </strong>While pediatric intraocular malignancies are rare, management requires frequent examinations under anesthesia (EUAs) which are financial costly. The purpose of the study was to measure operating room (OR) turnover costs and to estimate potential cost savings of reducing turnover time.</p><p><strong>Methods: </strong>Turnover time data for EUAs with a single ocular oncology provider at the University of Michigan were analyzed from 2021 to 2023. Direct cost of OR turnover was set at USD 25.73 per minute, and turnover time after business hours utilized a cost multiplier for overtime costs. A sensitivity analysis for turnover reduction savings was based on reducing turnover times to a goal turnover time. Primary outcomes were total and average turnover time and costs for pediatric ocular oncology EUAs. Secondary outcomes included the potential cost savings associated with reduced turnover time goals.</p><p><strong>Results: </strong>158 EUAs with valid turnover times were included. Total turnover time and costs were 5,034 min and USD 134,104. Average (standard deviation) turnover time and costs were 31.9 min (19.0) and USD 848.76 (USD 487.48). A majority of cases (65%) had turnover time less than 30 min, though a minority (23%) had a turnover time less than 20 min. By reducing maximum turnover time to 20 min, a total of USD 52,057 could be saved across these cases or USD 329 per case.</p><p><strong>Conclusions: </strong>Turnover time accounts for a notable proportion of OR costs, particularly for shorter cases. The average pediatric ocular oncology case had nearly USD 850 of turnover costs, much of which may be avoidable. Actions aimed at reducing turnover time are likely to have high return on investments if they are successful.</p>","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":"10 4","pages":"247-251"},"PeriodicalIF":0.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11627585/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142807649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Belzutifan in Individuals with von Hippel-Lindau Retinal Hemangioblastomas: Institutional Experience and Review of the Literature.","authors":"Farzad Jamshidi, Lola Lozano, Budd Tucker, Jean Andorf, Elliott Sohn, Edwin Stone, Andrew Groves, Yousef Zakharia, H Culver Boldt, Elaine Binkley","doi":"10.1159/000539434","DOIUrl":"10.1159/000539434","url":null,"abstract":"<p><strong>Introduction: </strong>The systemic HIF-2 alpha inhibitor, belzutifan, has been approved for use in patients with von Hippel-Lindau disease (VHL)-associated renal cell carcinoma, central nervous system (CNS) hemangioblastomas, and pancreatic neuroendocrine tumors. This drug has also shown promise in controlling VHL retinal hemangioblastomas (RHs), but little work has been published on the use of the drug in this setting.</p><p><strong>Methods: </strong>We conducted a retrospective review of patients with VHL-associated RHs followed by the retina service at our institution who were treated with systemic belzutifan. Patient age, gender, genotype, presence of systemic tumors, indication for the drug, initial dose, adjusted dose, side effects, and tumor response were recorded. We also conducted a literature search for all manuscripts describing the effect of belzutifan on VHL-associated ocular tumors.</p><p><strong>Results: </strong>We identified 12 eyes of 7 patients with VHL-associated ocular tumors who were treated with belzutifan at our institution. Of these, 5 eyes of 3 patients had progressing ocular tumors when belzutifan was started. Of the 7 total patients, 2 were treated for renal cell carcinoma, 2 for CNS hemangioblastomas, 2 for RHs, and one for pancreatic neuroendocrine tumors. Initial dose was 120 mg PO daily in 6 patients and 80 mg PO daily in 1 patient. The dose was reduced in all but 1 patient due to side effects. The ocular tumors were controlled in all patients with an average follow-up of 13 months (range 4-24 months). Literature review identified 7 manuscripts that described belzutifan-mediated control of ocular tumors in patients with VHL-associated RHs in 21 patients.</p><p><strong>Conclusion: </strong>The drug belzutifan shows great promise for controlling RHs and preventing vision loss in patients with VHL. Further work needs to address the optimal dose, role of the drug as a neoadjuvant therapy, and long-term efficacy and tolerability of the drug in a larger cohort of patients with ocular tumors.</p>","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":"10 3","pages":"154-161"},"PeriodicalIF":0.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368390/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Description and Characteristics of Ocular Tumor Lysis Syndrome.","authors":"Talisa E de Carlo Forest, Scott C N Oliver","doi":"10.1159/000538761","DOIUrl":"10.1159/000538761","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of the study was to describe and evaluate characteristics of ocular tumor lysis syndrome (OTLS) in eyes with uveal melanoma.</p><p><strong>Methods: </strong>Retrospective chart review of all patients with OTLS at the University of Colorado from 2009 to 2021. Data collected included patient demographics, tumor characteristics, radiation dosimetry, gene expression profiling (GEP), OTLS characteristics, management, and outcomes.</p><p><strong>Results: </strong>Seven eyes of seven patients with uveal melanoma treated with I-125 brachytherapy developed OTLS. Average age was 59 years (range 32-83). Mean apical height was 8.6 mm (range 6-11); mean diameter was 12.7 mm (range 8.5-15.3). All tumors were treated with plaques ≥16 mm in diameter. On presentation, 5/7 tumors had subretinal fluid, and 6/7 had collar-button configuration. OTLS presented as extensive pigment dispersion in the vitreous in all eyes, subretinal pigment and/or retinal detachment in 4/7 eyes, vitreous hemorrhage in 2/7 eyes, and anterior chamber pigment in 3/7 eyes. Four tumors were GEP class 1, two were class 2, and one was unclassified. Biopsy route was trans-scleral in 4/7 eyes and trans-vitreal in 3/7 eyes. OTLS occurred 2-4 weeks after an intraocular procedure in 5/7 eyes. All underwent pars plana vitrectomy. Cytology of the vitreous, obtained in five cases, showed pigment laden macrophages and hemorrhage, but only 1/5 eyes had viable malignant cells. Four eyes were stable at the last follow-up, two were enucleated, and one had no light perception from pigmentary glaucoma. Poor vision (<20/200) occurred in 6/7 cases. Three patients died from metastasis (tumors were GEP class 2, GEP class without subclassification, and no GEP classification performed).</p><p><strong>Conclusions: </strong>OTLS is a rare but devastating complication of uveal melanoma. Common characteristics included large plaque diameter, presence of subretinal fluid, and collar-button shape. The extensively dispersed pigment is typically not malignant. Though poor vision is common, enucleation may be avoided in most eyes through vitreoretinal surgical repair.</p>","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":"10 3","pages":"139-145"},"PeriodicalIF":0.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368393/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ruthenium-106 Plaque Brachytherapy for Circumscribed Choroidal Hemangioma: A Case Series and Review of Literature.","authors":"Islam Y Swaify, Hany Hamza, Ayman M Khattab, Mohamed-Sameh H El-Agha, Mostafa A El-Helw, Tamer A Macky, Dina H Hassanein, Shaymaa H Salah, Abdussalam M Abdullatif, Alia M Noureldine, Yasmine A Meqdad, Salma F Al-Etr, Layla El Qadi, Alaa E Fayed","doi":"10.1159/000539384","DOIUrl":"10.1159/000539384","url":null,"abstract":"<p><strong>Introduction: </strong>We aim to report the anatomical and functional outcomes of ruthenium-106 brachytherapy in the management of circumscribed choroidal hemangiomas (CCH).</p><p><strong>Methods: </strong>This is a single-center, retrospective case series including patients with unilateral symptomatic CCH treated with ruthenium-106 brachytherapy at the Cairo University Ocular Oncology Service. Patient records were analyzed for patients' demographics, best corrected visual acuity (BCVA), tumor dimensions (thickness and largest base diameter), foveal subretinal fluid, radiation-related complications, and recurrence.</p><p><strong>Results: </strong>Seven patients were included in the study (including 6 males) with a mean age of 39.3 ± 15.4 years; ruthenium-106 plaque was used to deliver 50 Gray to the tumor apex. After a mean follow-up duration of 12.5 months, all patients had significant improvement in BCVA after treatment, mean tumor height decreased significantly from 4.76 ± 1.76 mm to 1.70 ± 1.2 mm (<i>p</i> value 0.01). The largest tumor base diameter also decreased significantly from 9.13 ± 2.68 mm to 4.65 ± 3.75 mm (<i>p</i> value 0.05). Subretinal fluid and exudative retinal detachment resolved in all patients, and no significant radiation-related complications were observed in any patient. None of the patients needed any further treatment or experienced recurrence within the follow-up period.</p><p><strong>Conclusion: </strong>Ruthenium-106 brachytherapy is an effective tool in the management of symptomatic CCH with a good visual prognosis and safety profile.</p>","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":"10 3","pages":"146-153"},"PeriodicalIF":0.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368397/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How Much Time Do Focal Treatments for Retinoblastoma Add to Anesthetic Exposure?","authors":"David H Abramson, Jacquelyn Gaccione, Christina Bracken, Todd Liu, Edith Guarini, Andrea Bobin, Angela Foerch, Melissa A Robbins, Ricardo Dodds Rojas, Jasmine H Francis","doi":"10.1159/000539488","DOIUrl":"10.1159/000539488","url":null,"abstract":"<p><strong>Introduction: </strong>Children with retinoblastoma have anesthesia for exams and treatment, but there is little information about how long treatment interventions (laser, cryotherapy, and intravitreal injections) add to routine exams under anesthesia (EUA). This information would be useful for planning operating room schedules, staff schedules, family expectations, and billing.</p><p><strong>Methods: </strong>A retrospective, single-center, Institutional Review Board (IRB) approved review of anesthesia duration for retinoblastoma children undergoing EUA with laser, cryotherapy, or intravitreal injections performed at MSK between January 2019 and November 2023.</p><p><strong>Results: </strong>Three hundred eight patients had 2,399 EUAs. The average EUA lasted 24.3 min (range 7-77 min) when no interventions were done. Laser photocoagulation added an average of 18.9 min (range 19-77 min), cryotherapy 26.1 min (range 27-75 min), and intravitreal injection 23.5 min (range 10-71 min) to the basic EUA time. Bilateral laser treatments took 8 min longer than unilateral treatments.</p><p><strong>Conclusion: </strong>EUAs for children with retinoblastoma can be performed relatively quickly. Interventions such as laser, cryotherapy, or intravitreal injections roughly double the time under anesthesia but in some cases can take much longer (>1 h).</p>","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":"10 3","pages":"182-188"},"PeriodicalIF":0.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368391/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathologic Features of Eyelid Sebaceous Gland Carcinoma Requiring Immunohistochemical Diagnosis.","authors":"Tatsuya Yunoki, Akio Miyakoshi, Atsushi Hayashi","doi":"10.1159/000538537","DOIUrl":"10.1159/000538537","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of the study was to evaluate the clinicopathological features of eyelid sebaceous gland carcinoma (SGC), which requires immunohistochemical examination for a definitive diagnosis.</p><p><strong>Methods: </strong>Twenty-seven patients with a final diagnosis of eyelid SGC at Toyama University Hospital between April 2016 and April 2022 were retrospectively studied. In cases with a strong clinical suspicion of SGC, if the initial pathological diagnosis by hematoxylin-eosin staining was non-SGC, additional detailed pathology was performed, including immunostaining for adipophilin (ADP) and androgen receptor (AR).</p><p><strong>Results: </strong>Five patients (18.5%) had a diagnosis other than SGC, including three with squamous cell carcinoma (SCC), one with basal cell carcinoma, and one with Bowen disease. In these 5 cases, detailed pathology, including immunostaining for ADP and AR, was performed again, which ultimately led to the diagnosis of SGC. ADP was positive in all 5 cases, and AR was positive in 4 cases. The 3 patients diagnosed with SCC were characterized by a high Ki-67 index, active mitosis, and relatively low differentiation.</p><p><strong>Conclusion: </strong>SGC can be pathologically diagnosed in other cancers, such as SCC and BCC. When SCC was diagnosed, it was often hypo-differentiated and required more attention. Immunostaining for ADP and AR is invaluable for confirming SGC diagnosis.</p>","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":"10 3","pages":"131-138"},"PeriodicalIF":0.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368396/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum.","authors":"","doi":"10.1159/000537728","DOIUrl":"https://doi.org/10.1159/000537728","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1159/000533308.].</p>","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":"10 1","pages":"63"},"PeriodicalIF":0.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11937980/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143720609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Periocular Sebaceous Carcinoma: case audit from the National Specialist Ophthalmic Pathology Service in Liverpool from 2009 to 2022, to assess the diagnostic utility of PRAME expression.","authors":"Amizatul Aini Salleh, Y. Krishna, Sarah E. Coupland","doi":"10.1159/000535169","DOIUrl":"https://doi.org/10.1159/000535169","url":null,"abstract":"Introduction: Periocular sebaceous carcinoma (PSC) remains a common diagnostic pitfall both clinically and histomorphologically. PRAME (PReferentially Expressed Antigen in MElanoma) has been studied in the various neoplasms as proposed as diagnostic and therapeutic markers. PRAME is expressed in normal sebaceous units and in some sebaceous lesions; however, its utility in sebaceous carcinoma diagnosis has not yet been extensively investigated. \u0000We conducted a 13-year retrospective review of the patients diagnosed with PSC at the National Specialist Ophthalmic Pathology Service in Liverpool. Herein, we report the histomorphological and immunohistochemical (IHC) features of these tumors, particularly PRAME expression in this cohort.\u0000\u0000Methods: Thirty-one PSC cases diagnosed between 2009 to 2022 were retrieved from the histopathology archives. Twenty cases diagnosed as invasive PSC and 11 cases with in-situ PSC were included. The hematoxylin and eosin (H&E) slides and previously-performed IHC slides were reviewed; clinical information data were obtained. Cases with an adequate tissue were also stained for PRAME (PReferentially expressed Antigen in MElanoma) and adipophilin (if not already performed). \u0000\u0000Results: In total, there were 24 females and 7 males diagnosed with PSC, ranging from 55 to 90 years (median, 78 years). The types of specimens received were: 11 conjunctival mapping biopsies, 19 excisions/wedge resections, and 1 orbital exenteration. The eyelid was the commonest site involved (n=24), followed by eyelid with conjunctiva (3), and conjunctiva alone (4). All patients presented with the clinical suspicion of malignancy. \u0000Histologically, 11 invasive PSC (55%) exhibited poorly differentiated morphology, composed of predominantly atypical basaloid cells with minimal sebocytic differentiation; 9 cases (45%) were moderately-differentiated with noticeable finely multivacuolated cytoplasm; and 3 (15%) showed associated comedo-necrosis. Most invasive PSC showed moderate to brisk mitotic activities. \u0000Of those cases with available immunostains (n=31), 25 (80.6%) expressed adipophilin; 18 (58.1%) Ber-EP4; 14 (45.2%) epithelial membrane antigen (EMA); and 5 (16.1%) both androgen receptor and perforin positivity. PRAME expression was seen in normal sebaceous glands; however, only (5/19; 26%) of invasive PSC showed focal weak-to-moderate PRAME positivity, and mostly in moderately-differentiated tumors. None of the in-situ PSC were PRAME positive. \u0000\u0000Conclusions: Most PSC are moderate- to poorly-differentiated. Although PRAME is expressed in normal sebaceous units, it appears less useful as diagnostic marker for PSC, especially in poorly-differentiated tumors. In difficult cases, panels of immunohistochemical studies (Adipophilin, Ber-EP4 and EMA) achieve a definitive diagnosis.","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":"128 ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2023-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138982228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}